Rong et al previously reported that rosiglitazone as an agonist of PPARγ could improve impairments of mitochondrial biogenesis and PGC-1α expression in the adipose tissue of T2DM mice [23]. The gene discussed is PPARGC1A; the disease is type 2 diabetes mellitus.